Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Margin evaluation with fluorescence confocal microscopy during minimally invasive radical prostatectomy.

BJU international·2026
Same author

<i>TFE3</i>-Rearranged and <i>TFEB</i>-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances.

Cancers·2026
Same author

Systematic biopsies of the upper urinary tract: a tool to improve the diagnostic accuracy of ureteroscopy and characterization of upper tract urothelial cancer.

World journal of urology·2025
Same author

Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer.

European urology oncology·2025
Same author

Survival in Responders and Nonresponders of Neoadjuvant and Induction Chemotherapy in Invasive Urothelial Carcinoma of the Urinary Bladder: A Clinical and Pathological Stage-Matched Analysis.

Clinical genitourinary cancer·2025
Same author

Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study.

Histopathology·2025
Same journal

Focal Therapy for Localized Prostate Cancer: Maturing Evidence, Evolving Questions.

European urology·2026
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

EAU penile cancer guidelines 2009.

Giorgio Pizzocaro1, Ferran Algaba, Simon Horenblas

  • 1Second Urologic Clinic, Milan University, Ospedale S. Giuseppe, Milano, Italy. pizzocaro@iol.it

European Urology
|February 19, 2010
PubMed
Summary
This summary is machine-generated.

Updated European Association of Urology guidelines for penile squamous cell carcinoma (SCC) highlight the role of Human papillomavirus 16 and improved treatments. Early diagnosis and chemotherapy offer better outcomes for this rare cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

  • Urology
  • Oncology
  • Epidemiology

Background:

  • Penile squamous cell carcinoma (SCC) is a rare but aggressive malignancy.
  • Etiology, staging, and treatment of penile SCC are evolving.
  • Human papillomavirus 16 is implicated in 40-50% of penile SCC cases.

Purpose of the Study:

  • To summarize the updated 2009 European Association of Urology (EAU) guidelines for penile SCC.
  • To provide a condensed overview of recent advancements in managing penile cancer.

Main Methods:

  • Literature search for data up to December 2009.
  • Review of etiological factors, diagnostic improvements, and treatment strategies.
  • Analysis of evidence levels and grades of recommendations.

Main Results:

  • Human papillomavirus 16 identified as a key etiological factor.
  • Improved diagnostics enable earlier detection and more conservative treatments.
  • Adjuvant and neoadjuvant chemotherapy show promise for advanced/recurrent disease.
  • Centralization of care leads to treatment standardization and better outcomes.

Conclusions:

  • Guidelines reflect improvements in penile SCC management.
  • The rarity of penile SCC limits randomized studies, resulting in low evidence levels.
  • Advancements in diagnosis and treatment enhance organ preservation and patient outcomes.